Autumn Glory Partners’s Royalty Pharma RPRX Stock Holding History

Autumn Glory Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$336K	Sell	6,000 -4,000	-40%	-$208K	0.1%	165
2026 Q1	$480K	Hold	10,000	–	–	0.18%	125
2025 Q4	$386K	Hold	10,000	–	–	0.14%	146
2025 Q3	$353K	Hold	10,000	–	–	0.14%	139
2025 Q2	$360K	Buy	10,000 +3,000	+43%	+$99.4K	0.17%	134
2025 Q1	$218K	Buy	+7,000	New	+$222K	0.11%	166

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Autumn Glory Partners's RPRX Position: Q2 2026 in Review

Autumn Glory Partners reduced its Royalty Pharma (RPRX) stake by 40% in Q2 2026, selling an estimated $208K and leaving 6,000 shares worth $336K. The position accounts for 0.1% of the portfolio, ranked #165.

Autumn Glory Partners first reported a position in RPRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $480K in Q1 2026. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Autumn Glory Partners held 6,000 shares of Royalty Pharma worth $336K as of Q2 2026.
Autumn Glory Partners sold 4,000 Royalty Pharma shares in Q2 2026, an estimated $208K.
Royalty Pharma made up 0.1% of Autumn Glory Partners's portfolio in Q2 2026, its #165 holding.
Autumn Glory Partners first reported a position in Royalty Pharma in Q1 2025 and has held it in 6 quarters since.
Autumn Glory Partners's Royalty Pharma position peaked at $480K in Q1 2026.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Autumn Glory Partners's 13F filing for Q2 2026, filed 3 Aug 2026.